Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GLPG 
Galapagos NV ADR (GLPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: GLPG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $28.97
1 Year Target Price $28.97
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.96% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.90B USD | Price to earnings Ratio - | 1Y Target Price 28.97 |
Price to earnings Ratio - | 1Y Target Price 28.97 | ||
Volume (30-day avg) 6 | Beta -0.01 | 52 Weeks Range 22.36 - 31.23 | Updated Date 07/9/2025 |
52 Weeks Range 22.36 - 31.23 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -58.83% | Operating Margin (TTM) -211.68% |
Management Effectiveness
Return on Assets (TTM) -4.66% | Return on Equity (TTM) -6.36% |
Valuation
Trailing PE - | Forward PE 166.67 | Enterprise Value -1946651302 | Price to Sales(TTM) 6.59 |
Enterprise Value -1946651302 | Price to Sales(TTM) 6.59 | ||
Enterprise Value to Revenue 1.18 | Enterprise Value to EBITDA -31.5 | Shares Outstanding 65897100 | Shares Floating 64988226 |
Shares Outstanding 65897100 | Shares Floating 64988226 | ||
Percent Insiders - | Percent Institutions 22.24 |
Upturn AI SWOT
Galapagos NV ADR
Company Overview
History and Background
Galapagos NV was founded in 1999 in Mechelen, Belgium. It initially focused on providing drug discovery services before transitioning to developing its own proprietary pipeline of drug candidates. A significant milestone was the approval of Jyseleca (filgotinib) for rheumatoid arthritis in Europe and Japan. Over time, Galapagos has evolved into a fully integrated biopharmaceutical company.
Core Business Areas
- Research and Development: Focuses on discovering and developing novel therapies for diseases with high unmet medical needs.
- Commercialization: Involves the marketing and sales of approved therapies, such as Jyseleca, in relevant markets.
- Drug Discovery Services: Provides drug discovery services to other pharmaceutical companies, which was its original core business.
Leadership and Structure
The leadership team consists of the CEO, Chief Scientific Officer, Chief Medical Officer, and other key executives. The company is structured with departments focused on R&D, commercial operations, finance, and corporate affairs. The CEO is Dr. Paul Stoffels.
Top Products and Market Share
Key Offerings
- Jyseleca (filgotinib): A selective JAK1 inhibitor approved for rheumatoid arthritis and ulcerative colitis in certain markets (Europe, Japan). The market share varies by country, with competition from other JAK inhibitors like Xeljanz (tofacitinib) from Pfizer and Rinvoq (upadacitinib) from AbbVie. AbbVie and Pfizer are competitors. The total revenue from this product has been $177 million EUR in 2022.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. It is driven by innovation and the need for new therapies to address unmet medical needs.
Positioning
Galapagos is positioned as an innovative biopharmaceutical company with a focus on developing novel therapies for inflammatory diseases and other areas with high unmet need. Its competitive advantages include its proprietary drug discovery platform and its expertise in developing novel therapies. It is behind on revenue and earnings to the other larger competitors.
Total Addressable Market (TAM)
The TAM for inflammatory diseases is estimated to be in the billions of dollars annually. Galapagos aims to capture a significant portion of this market with its pipeline of drug candidates. For example, the JAK inhibitor market itself is expected to be $10+ billion. Their TAM is dependent on future successful pipeline products.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Proprietary drug discovery platform
- Experienced management team
- Approved product (Jyseleca) in certain markets
Weaknesses
- Reliance on partnered programs
- High R&D spending
- Geographic concentration in Europe
- Jyseleca not approved in the US
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Potential approval of pipeline candidates
- Growth in emerging markets
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- LLY
- BMY
Competitive Landscape
Galapagos faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Its advantages include its innovative drug discovery platform and its focus on specific therapeutic areas. Their total revenue is much lower than these competitors.
Major Acquisitions
CellPoint Technologies
- Year: 2007
- Acquisition Price (USD millions): 12
- Strategic Rationale: Expands Galapagos' capabilities in target discovery and validation.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by partnerships and the commercialization of Jyseleca. However, setbacks in clinical trials have hampered growth.
Future Projections: Future growth depends on the success of its pipeline candidates and expansion into new markets. Analyst estimates vary widely.
Recent Initiatives: Focusing pipeline efforts on immunology and other areas with a higher potential for success. Streamlining operations to reduce costs.
Summary
Galapagos NV ADR is a biopharmaceutical company with a focus on inflammatory diseases. Its strengths lie in its R&D capabilities and proprietary drug discovery platform, but its weaknesses include reliance on partnerships and high R&D spending. Opportunities exist for expansion into new therapeutic areas and strategic collaborations. Threats include regulatory hurdles and competition from larger companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Publicly Available Financial Data
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galapagos NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-05-06 | CEO & Executive Director Mr. Henry Gosebruch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 704 | Website https://www.glpg.com |
Full time employees 704 | Website https://www.glpg.com | ||
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.